FRA2A Is a CGG Repeat Expansion Associated with Silencing of AFF3

Citation for published version:

Digital Object Identifier (DOI):
10.1371/journal.pgen.1004242

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS Genetics

Publisher Rights Statement:
Copyright: © 2014 Metsu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
FRA2A Is a CGG Repeat Expansion Associated with Silencing of AFF3

Sofie Metsu1, Liesbeth Rooms1, Jacqueline Rainger2, Martin S. Taylor3, Hemant Bengani2, David I. Wilson3, Chandra Sekhar Reddy Chilamakuri4, Harris Morrison2, Geert Vandeweyer1, Edwin Reyniers1, Evelyn Douglas5, Geoffrey Thompson6,7, Eric Haan5,8, Jozef Gecz5,6, David R. FitzPatrick2,*, R. Frank Kooy1,*

1 Department of Medical Genetics, University of Antwerp, Antwerp, Belgium, 2 Medical and Developmental Genetics Section, MRC Human Genetics Unit, IGMM, University of Edinburgh, Edinburgh, United Kingdom, 3 University of Southampton, Centre for Human Development, Stem Cells and Regeneration, Human Genetics, Southampton, United Kingdom, 4 Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway, 5 Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia, 6 Department of Paediatrics, The University of Adelaide, Adelaide, South Australia, Australia, 7 Department of Paediatrics and Child Health, Flinders University, Adelaide, South Australia, Australia, 8 South Australian Clinical Genetic Service, SA Pathology (at Women’s and Children’s Hospital), Adelaide, South Australia, Australia

Abstract

Folate-sensitive fragile sites (FSFS) are a rare cytogenetically visible subset of dynamic mutations. Of the eight molecularly characterized FSFS, four are associated with intellectual disability (ID). Cytogenetic expression results from CGG trinucleotide-repeat expansion mutation associated with local CpG hypermethylation and transcriptional silencing. The best studied is the FRAXA site in the FMR1 gene, where large expansions cause fragile X syndrome, the most common inherited ID syndrome. Here we studied three families with FRA2A expression at 2q11 associated with a wide spectrum of neurodevelopmental phenotypes. We identified a polymorphic CGG repeat in a conserved, brain-active alternative promoter of the AFF3 gene, an autosomal homolog of the X-linked AFF2/FMR2 gene: Expansion of the AFF2 CGG repeat causes FRAXE ID. We found that FRA2A-expressing individuals have mosaic expansions of the AFF3 CGG repeat in the range of several hundred repeat units. Moreover, bisulfite sequencing and pyrosequencing both suggest AFF3 promoter hypermethylation. cSNP-analysis demonstrates mononucleic expression of the AFF3 gene in FRA2A carriers thus predicting that FRA2A expression results in functional haploinsufficiency for AFF3 at least in a subset of tissues. By whole-mount in situ hybridization the mouse AFF3 ortholog shows strong regional expression in the developing brain, somites and limb buds in 9.5–12.5dpc mouse embryos. Our data suggest that there may be an association between FRA2A and a delay in the acquisition of motor and language skills in the families studied here. However, additional cases are required to firmly establish a causal relationship.


Editor: Christopher E. Pearson, The Hospital for Sick Children and University of Toronto, Canada

Received July 24, 2012; Accepted February 2, 2014; Published April 24, 2014

Copyright: © 2014 Metsu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Institute for the Promotion of Innovations through Science and Technology in Flanders (IWT Vlaanderen). JG was supported by NHMRC Research Fellowship. HB was funded by the FP7 NeuroXsys project. DRF, MST and JR are funded by core program grants from the Medical Research Council (UK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: david.fitzpatrick@ed.ac.uk (DRF); frank.kooy@uantwerpen.be (RFK)

Introduction

Dynamic mutations are heritable unstable expansions of short, genomic repeat sequences. Various pathogenic mechanisms have been associated with dynamic mutations [1,2] and at least 40 neurodevelopmental, neurodegenerative and neuromuscular disorders are known to be caused by these types of mutations [3,4]. Expansions of these unstable sequences may occur in promoters, coding regions, introns and 3' and 5' untranslated regions (UTR) of genes [5,6,7]. Known and putative disease mechanisms include aberrant splicing [8], loss of gain of function of the encoded protein [9,10], the expanded repeat itself [11] or its RNA transcript [12,13] and Repeat Associated Non-ATG translation (RAN translation) [14,15]. The size threshold at which a repeat becomes unstable and/or pathogenic varies widely, from the expansion of only a few trinucleotide repeats in e.g. ARX-associated infantile epileptic encephalopathy (MIM 308350) to over a thousand repeats in e.g. DMPK-associated myotonic dystrophy (MIM 160900), FXN-associated Friedreich ataxia (MIM 229900) and FMR1-associated fragile X syndrome (MIM 300624) [16,17,18].

Fragile sites represent a specific subset of dynamic mutations that are visible as gaps or breaks on metaphase chromosomes from cells cultured under specific conditions. Fragile sites are categorized by the nature of the inducing culture condition and the population frequency of the mutation [19]. FRAXA is a rare, folate sensitive fragile site (FSFS) associated with a trinucleotide repeat (CGG) expansion mutation in the 5' UTR of the FMR1 gene resulting in fragile X syndrome, the most common inherited intellectual disability syndrome [20]. Twenty-six other FSFS have been reported cytogenetically but only eight of these have been molecularly characterized: FRAXA [20], FRAXE [21], FRAXF [22], FRA16A [23], FRA11B [24], FRA10A [25], FRA12A [26]...
and FRA11A [27]. To date, all characterized FSFS are due to a CCG/CGG trinucleotide repeat expansion. The expanded repeat and any adjacent CpG island become hypermethylated and transcriptionally silenced at a locus-specific repeat size-threshold [28]. At least four of the eight known fragile sites this silencing of the associated gene(s) lead to intellectual disability syndromes such as fragile X. In this work we describe molecular characterization of an autosomal FSFS called FRA2A on chromosome 2. As the molecular cause of FRA2A, we identify an expansion of a CGG repeat which subsequently results in silencing of the neighbouring gene AFF3. This gene is one of the four autosomal paraloggs of the AFF2/ FMR2 gene which, when mutated, is the cause of the FRAXE syndrome. We find that FRA2A expression is associated with highly variable developmental anomalies in the three FRA2A families studied.

### Results

FRA2A is due to expansion of a polymorphic CGG repeat within AFF3

Using the simple repeat track on UCSC genome browser (GRCh37/hg19) we identified three candidate CGG repeats in the FRA2A containing region (2q11-12). One of these repeats is located within the LAF4/AFF3 gene (chr2:100721261–100721286; hg19), an autosomal homolog of the FRAXE-associated FMR2/ AFF2 gene. In order to determine whether this CGG-repeat is expanded in FRA2A we used metaphase FISH analysis on a FRA2A-expressing individual (Figure 1; AII.3) with the BAC clone RP11-549H5 (chr2:100,588,792–100,759,365; hg19) encompassing the repeat. The FISH signal spanned the FRA2A fragile site (Figure 2A). Consistent with this the FISH signals from probes RP11-436F6 (AC010736) and RP11-506F3 (AC074387) were centromeric and telomeric to FRA2A, respectively. To establish co-location of the CGG repeat with the fragile site, long-range PCR-generated probes L10K (chr2:100721983–100733233; hg19) and L18K (chr2:100700447–100718834; hg19) were targeted to the genomic regions on either side of the (CGG) n repeat. These probes did indeed flank the fragile site, locating FRA2A to a 3.1 kb interval within the AFF3 gene (Figure 2B). The second red (L18K) FISH signal observed at 2q13 (Figure 2B) is the result of two copies of a 24 kb low copy repeat flanking the NPHP1 gene (Figure 2C) (chr2: 110520380–110538822 and chr2:111347822–111366260;

---

Figure 1. Description of FRA2A Families A–C. Females are represented by circles, males by squares. The percentage of cells showing FRA2A expression are indicated on the bottom right-hand side of the symbol. As discussed in the text the 4% FRA2A expression seen in individual AI.1 represents a false positive. The case number used to indicate the FRA2A carriers in the text is given on the top left-hand side of the symbol. N within a symbol indicated individuals expression of the fragile site was not examined or observed. The associated phenotypes in individuals All.3, All.4, Bl.1 and Cl.I.1 are detailed in the boxed symbol key. The proband in each family is arrowed.

doi:10.1371/journal.pgen.1004242.g001
A copy of this sequence is also located adjacent to the CGG-repeat within the **AFF3** gene in the region covered by L18K. PCR-based amplification and sequencing of the **AFF3** CGG repeat in 200 control chromosomes revealed it to be highly polymorphic with a length ranging from 3 to 20 copies (Figure 3). The most frequent CGG allele contains eight repeats (as does the genomic reference sequence; chr2:100721261–100721286; hg19). To exclude the possibility that apparently homozygous control individuals are in fact heterozygous for the detected allele in combination with a large expansion that is not detected by this protocol, we amplified these samples with gene specific repeat primed PCR (Asuragen Inc., Austin Texas, USA). This protocol enables us to detect expansions up to 300–500 repeats. However, no expanded repeats were detected in control chromosomes, and the genotype distribution agreed with Hardy-Weinberg equilibrium (P > 0.05).

PCR amplification of the repeat in the FRA2A-expressing individuals from AI.1, AII.3, AII.4, AIII.1, BII.1 and CII.1 (Figure 1) showed a single CGG allele in the normal size range. An additional smaller fragment was detected in subject AII.4. Sequence analysis of the smaller PCR product showed a 134-bp deletion encompassing the entire CGG repeat as well as some flanking sequences (Figure S1). This deletion was not detected in 800 control chromosomes. To visualize the repeat expansion in the FRA2A-positive individuals, we performed Southern blotting on HindIII digested genomic DNA of all available members of the three families (AI.1, AII.3, AII.4, AIII.1, BI.2, BI.1, CI.1, CI.2 and CI.3) and control samples. A 4.4 kb fragment was observed in all cases and controls. In five affected FRA2A-positive individuals we detected additional large fragments or smears compatible with the presence of an expanded allele (Figure 4). Two FRA2A-negative parents of FRA2A-positive individuals (BI.2 and CI.2) showed additional larger fragments indicative of repeat expansion. No evidence of an expanded fragment was observed in the control samples or in FRA2A-negative individual CI.1. Interestingly, individual AI.1 who had been reported as showing a low level of FRA2A-positive cells showed no fragments suggestive of an expansion mutation. A Southern blot of the same samples after *Nco*I digestion gave very similar results (data not shown).

A gene specific repeat-primed PCR assay was used for accurate sizing of the repeat expansion mutations. The mothers in family B and C both showed a slightly expanded allele (±120 and 166 repeat units, respectively) in addition to an allele in the normal size range (15 and 17 repeat units, respectively) while their offspring show one allele of 8 units compatible with paternal inheritance and one allele with a large expansion of more than 300 units (Figure S2). This strongly suggests that the expanded allele in both families was inherited from the mother (Table 1). In family A, the apparently FRA2A-positive individual AI.1 showed no evidence of an expanded allele on either Southern blot analysis or on repeat primed PCR. This apparent discrepancy could be resolved.
genetically using the microsatellite markers (D2S2209/AF-MA246XE9 and D2S2311/AFMB355ZG1, Figure S3). The FRA2A-positive daughters of AI.1, AII.3 and AII.4, were shown to have inherited a different non-expanded allele (8 CGG units) from him, while they share a common allele with the mother (AI.2). Their FRA2A-positive grand-daughter, AIII.1 also inherited this maternal allele. The expansion was therefore probably inherited from AI.2, with the 4% FRA2A expression in AI.1 representing a false-positive cytogenetic result. Unfortunately DNA was not available from AI.2 to determine if she also carried an intermediately expanded allele.

Characterization of the two major AFF3 transcriptional start sites (TSS)

The RefSeq AFF3 gene model consists of 23 coding exons and two 5’ non-coding exons together spanning 538 kb genomic DNA [33]. Here, the 5’ non-coding exons are named exons 1 and 2 with the first coding exon called exon 3. An AFF3-specific cDNA probe encompassing the final 5 exons was used for northern blot analysis. A major transcript of approximately 8 kb, corresponding to the predicted size was detected in several tissues, including brain, placenta and lung (data not shown).

To determine the precise location of the AFF3 transcriptional start sites (TSSs) in relation to the expanded repeat we used Cap Analysis of Gene Expression (CAGE) data from the FANTOM4 consortium. FANTOM4 produces sequence tags from the 5’ end of mRNAs from many different tissue sources and species and maps these to the reference genome [34]. Mapped CAGE tags reveal the sites of transcription initiation at single nucleotide resolution and provide a semi-quantitative measure of steady state mRNA levels for those transcripts using a tags per million (TPM) metric. The TPM scores for three different human tissue groups (brain, immune and other tissues) are plotted in Figure 5B. AFF3 is transcribed in telomeric to centromeric orientation and the x axis of these graphs represent the hg19 genomic coordinates. The location of the 25 annotated exons of the RefSeq model of the AFF3 gene (NM_001025108) is represented above the graphs using the same genomic coordinates. To assess the transcriptional activity of AFF3 during early brain development we mapped transcriptome sequencing reads of mRNA (RNA-seq) from three different human fetal brain samples to the regions surrounding the TSS identified by CAGE (Figure 5C).

CAGE tag sequencing demonstrates two robust TSSs. The most 5’ TSS corresponds to the 5’ end of exon 1 at position chr2:100759169 (GRCh37/hg19). This TSS is highly expressed in immune tissues with a mean of 300 tags per million shown by the blue bar in the middle graph (Figure 5B). There is no obvious transcription of exon 1 on RNA-seq from human fetal brain (Figure 5C, left-hand side). A second robust TSS was identified in CAGE data from brain and other tissues which mapped within intron 2 as shown by the blue bars in the top and bottom graphs in Figure 5B. The highest levels are seen in the brain (mean of 60 tags per million). An expanded representation of this region is shown in Figure 5C. This shows no evidence of transcription of exon 2 but strong expression in exon 3. This also shows evidence of an alternative exon 1 immediately 3’ to the TSS (Figure 5C, right hand side, black arrow). The TSS lies immediately downstream of the CGG repeat (Figure 5D) suggesting this expansion prone repeat is located within the core of an alternate AFF3 promoter.

Figure 3. Allele frequencies of the FRA2A associated CGG repeat in a population of 100 control individuals. PCR amplification of the repeat and subsequent sequencing in 200 control chromosomes revealed that it is highly polymorphic with a length ranging from 3 to 20 copies. The most commonly found allele contains eight repeated units.

doi:10.1371/journal.pgen.1004242.g003
The location and tissue specific activity of the AFF3 promoters are similar in mouse AFF3 FANTOM4 CAGE data also encompasses a range of mouse tissues. From this we can demonstrate that both the exon 1 TSS and intron 2 TSS are evolutionarily conserved and functional TSSs. Although the CGG repeat itself is not conserved, a region of low compositional complexity flanked by highly constrained non-coding sequences is a conserved feature of the intron 2 TSS promoter (Figure 5).

Whole mount in situ hybridization (WISH) using riboprobes targeted to the 3'UTR of Aff3 was used to determine the developmental expression pattern in mouse embryos at 9.5, 10.5, 11.5 and 12.5 days post coitus (dpc). This has shown site and stage specific expression of Aff3. The most striking areas of expression are in the somites, the upper limb buds, the diencephalon/prosomere I and the fusing primary palate (Figure 6).

AFF3 promoter regions are hypermethylated in individuals with the FRA2A CGG-repeat expansion

In all rare, folate-sensitive sites characterised to date, CGG repeat expansions are associated with hypermethylation of the surrounding CpG island. Bisulfite sequencing indicated hypermethylation of the CpG island in all five affected FRA2A carriers AII.3, All.4, AllI.1, BII.1 and CIll.1, while in healthy control individuals this region was not methylated (figure S4). In order to quantify the methylation level, we subsequently subjected all samples to pyrosequencing. This technique allows accurate quantification of methylation across individual CpG sites [35]. A methylation frequency of 50% would be consistent with complete methylation of the expanded allele as all affected individuals in this study are heterozygous. We analyzed a short region of genomic DNA (chr2:100088460–100089451; hg19) adjacent to the CGG repeat in all available family members, containing four analysable CpG dinucleotides (Figure S1 and Table 2). Methylation percentages are congruous across the 4 CpG-sites in each individual (p-values ranging from 0.417 to 1.000) and are consistent with hypermethylation of the CGG repeat region in individuals carrying an expanded allele. There is some suggestion that the methylation frequency may be increasing upon generational transmission.

To exclude a non-specific effect of increasing age on the methylation of this region, we pyrosequenced 72 individuals from 24 unrelated two-generation families. The ages within this control group varied between 0 and 11 years for the children and between 23 and 53 years for the parents, which is comparable to the age distribution in our FRA2A families at the time of DNA collection. No methylation above the threshold was detected in any control individual (data not shown). In the FRA2A-carriers the methylation level for each of the four CpG sites differed significantly from the level determined in this control population (p-values < 0.001 for CpG site 1, 2 and 4 and p<0.004 for CpG site 3), suggesting that expansion of the repeat is associated with hypermethylation of the region surrounding the repeat.

In AII.4, mosaic for a CGG-repeat expansion and a deletion, the promoter region on the expanded allele was hypermethylated as determined by bisulfite sequencing. The allele with the 134-bp deletion was not methylated, as determined by Southern blotting after double digestion with BamHI and NotI (data not shown).
Monoallelic expression of the AFF3 gene in FRA2A carriers

The level of AFF3 expression in lymphoblastoid cell lines is too low to be reliably measured by RT-qPCR. To determine if FRA2A results in transcriptional silencing of AFF3 in cis, we utilized single nucleotide polymorphisms (SNP) mapping within the open reading frame. Two such SNPs were found to be heterozygous in the genomic DNA of affected FRA2A carrier BI.1. Rs4851214 maps to exon 14 and heterozygous individuals display both an T and a C peak (c.1499T/C) on Sanger sequencing, while rs13427251 maps to exon 25 and heterozygotes for this SNP show both an A and a T peak (c.5475A/T). Sequencing cDNA from BI.1, revealed only a C peak at rs4851214 (Figure 7) and only the A allele peak was seen for rs13427251. These results are consistent with monoallelic expression of AFF3 in this individual. Genomic DNA from BI.1’s mother (BL.2) is homozygous for the rs13427251 T allele (g.5475T/T) indicating that it is the maternal T allele carrying the CGG expansion that is silenced in BI.1. cDNA of BL.2 showed a heterozygous signal for rs4851214 (c.1499T/C) indicating that both AFF3 alleles are transcribed in the mother despite partial methylation of her expanded allele.

Analysis of clinical phenotypes associated with FRA2A

Six FRA2A carriers were initially included in this study (Figure 1, Table 3), four in Family A and one each in Families B and C. Individual AII.1 is currently too young to make any conclusion about cognitive development. Individual AII.1 has no discernible affected phenotype and he also has the lowest expression of the fragile site. The molecular analysis presented above strongly suggests that the 4% apparent expression of this case represents a false positive and so was excluded from the clinical analysis. Two FRA2A carriers AII.3 and AII.4 are adults; both had global delay in their neurocognitive development to a level that merited genetic investigations during childhood and their long-term placement in special educational facilities. However, as adults both of these individuals are functioning at a normal level and are in full time employment. This raises the possibility that they had a true delay in development rather than a fixed disability. Something similar is observed in FRAXE patients as most adult FRAXE males adapt to live a normal life. Individual CII.1 was born prematurely and had significant respiratory distress, which confounds the unambiguous interpretation of the cause of her mild developmental delay. BI.1 has the most significant delay, currently without a plausible non-genetic explanation. Thus all four of the characterized true FRA2A carriers did have significant delay in their motor and language development.

To determine whether the FRA2A carriers with neurodevelopmental anomalies had additional mutations in the protein coding region of the AFF3 gene, mutation analysis of all coding exons was performed. No sequence abnormalities were detected in any of the affected FRA2A carriers, except in subject AII.4, in which a 6-bp deletion was identified in exon 14, removing two amino acids: Threonine and Alanine (position 619 and 621 respectively) (Figure 5A). Both amino acids are found in a region, enriched with proline, serine and glutamic acid residues and located between the transactivation domain and the nuclear localisation signal (NLS). According to different prediction software (mutationtaster, mutation assessor, Indelz), the deletion is benign. Moreover, this 6-bp in-frame deletion was also present in the unaffected father (AI.1).

Discussion

We provide compelling evidence that the molecular basis of the FSFS FRA2A is a CGG repeat expansion in an alternative promoter which is active in the brain and is located in the intron immediately 5’ to the first coding exon of the major AFF3 transcript. The FRA2A-associated repeat is polymorphic in the general population. Repeat primed PCR showed all individuals with an expansion of over 300 repeat units expressed FRA2A in more than 20% of their cells. The expansion was associated with hypermethylation of a CpG island adjacent to the alternative promoter and, in at least one case, resulted in transcriptional silencing of AFF3. These results are consistent with the epigenetic effects that have been described in other FSFS. Within each of the three families studied here higher levels of methylation correlate well with neurodevelopmental delay, higher repeat size and silencing of AFF3. However, there are striking disparities in the absolute levels of methylation observed between the families. For example individuals AII.3 and AII.4 both have >300 repeats and had evidence of neurodevelopmental delay during childhood but have lower levels of methylation than BI.2 (~120 repeats, biallelic expression of AFF3) and CII.2 (106 repeats) neither of whom showed evidence of developmental delay. A likely explanation for this is that the assay used here was performed on peripheral blood-derived cells whereas the phenotype in which we are interested is developmental and neural. Many developmental loci appear to show tissue specific differences in DNA methylation [36]. In this regard the ability to model brain development using cerebral organoids from patient-derived pluripotent cells [37] may enable more interpretable transcriptional and epigenomic analyses of the consequences of CGG-repeat expansion on AFF3.

Nonetheless, all individuals for whom a significant methylation frequency was measured, show an expanded allele in the pre- or full mutation range. Repeat sizes of >300 do correlate with neurodevelopmental effects and expression of the fragile site in a significant percentage of cells. Carriers of an expanded allele in the premutation range are phenotypically normal but may show lower levels of expression of the fragile site.
In one individual (AII.4) a mosaic deletion of 134-bp removed the entire CGG repeat and the CpG island on the deleted allele remains unmethylated (data not shown). A similar combination of a full mutation with an expanded repeat and a deletion encompassing the repeat has been reported in several fragile X syndrome patients and recently also in a myotonic dystrophy type 1 case [38,39]. In the fragile X syndrome, the phenotype of deletion cases is often indistinguishable from that of carriers of an expanded repeat, a reported exception being an unaffected individual where the deletion is the major allele present, and the transcription and translation start sites are preserved [40].

**AFF3** belongs to a family of nuclear transcription activating factors including **AFF1/AF4**, **AFF2/FMR2** and **AFF4/AF5q31** [33,41,42]. These proteins form super elongating complexes (SEC).
with active P-TEFb (positive transcription elongation factor) and AF9/ENL. SECs regulate the induction and expression of different subsets of genes. *AFF3* is the closest paralog of *AFF2*, and is 36% identical on the amino acid sequence level. They share functional domains including the N-terminal Homology Domain (NHD), the C-terminal Homology Domain (CTHD) involved in intranuclear localization and binding of G-quadruplex RNA structures, and the ALF domain that promotes protein degradation through the proteasome pathway and the transactivation domain (TAD). Intriguingly, the highly conserved intron 2 TSS sequences and to a lesser extent the CGG repeat itself, are predicted to have a strong propensity to form G-quadruplex

**Figure 6. Site and stage specific expression of *Aff3* in mouse embryos.** A. photomicrograph of a lateral view of a 12.5 dpc embryo with the blue staining representing the gene expression of Aff3. The only area of strong expression at this stage is in the hand plate. B. show a false coloured but unthresholded image of the brightfield optical projection tomography (OPT) scan of a 11.5 dpc embryo with digital sagittal and coronal sections from the same embryo shown in C and D. Strong expression is seen in the somites, upper limb bud, the fusing primary palate and the diencephalon and prosomere1 regions of the developing brain.

doi:10.1371/journal.pgen.1004242.g006
structures (Figure 5D, orange bars) with the most downstream of these being present in the 5' UTR of the produced transcript. Given that AFF3 is known to bind G-quadruplexes, there is the potential for AFF3 autoregulation at this promoter. Both AFF2 and AFF3 localize to nuclear speckles and modulate splicing efficiency [43]. The expression pattern of murine Aff3 overlaps to a considerable extent with that of murine Aff2 [43,44].

FRAXE is associated with loss of expression of AFF2 through dynamic repeat expansion of a CGG repeat in the 5' UTR. FRAXE causes an X-linked non-syndromic intellectual disability [45]. AFF2 may play an important role in learning, memory, and language-learning processes [46]. Moreover, rare missense variations in the highly evolutionary conserved sites of the AFF2 gene might be associated with autism spectrum disorder [47]. The Aff2 knockout mouse model shows specific cognitive deficits, including an impaired conditioned fear memory over longer periods and enhanced long-term potentiation in the hippocampus [48,49]. Aff3 expression is upregulated in cortical neurons during the initial steps of cortical differentiation and is downregulated in postnatal cortex, indicating its involvement in brain development [44]. We have shown that Aff3 shows strong regional expression in the developing mouse brain.

AFF3 is thus a reasonable candidate for the neurodevelopmental features seen in FRA2A carriers in our families. Our data predict

Table 2. Pyrosequencing reliably quantified the methylation of four consecutive CpG dinucleotides per individual (chr2:100721843–100721885; hg19).

<table>
<thead>
<tr>
<th></th>
<th>CG</th>
<th>C</th>
<th>G</th>
<th>A</th>
<th>C</th>
<th>A</th>
<th>G</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.1</td>
<td>5±1.6</td>
<td>4±1.3</td>
<td>5±0.5</td>
<td>–</td>
<td>2±0.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II.3</td>
<td>18±2.0</td>
<td>17±3.8</td>
<td>20±3.4</td>
<td>–</td>
<td>14±2.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II.4</td>
<td>24±2.9</td>
<td>21±2.9</td>
<td>24±3.8</td>
<td>–</td>
<td>18±2.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III.1</td>
<td>26±2.7</td>
<td>22±1.5</td>
<td>25±3.0</td>
<td>–</td>
<td>21±1.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.2</td>
<td>27±3.1</td>
<td>26±3.1</td>
<td>28±3.6</td>
<td>–</td>
<td>22±3.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II.1</td>
<td>45±0.4</td>
<td>44±3.2</td>
<td>48±2.4</td>
<td>–</td>
<td>33±2.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.1</td>
<td>5±1.7</td>
<td>3±1.3</td>
<td>3±1.7</td>
<td>–</td>
<td>2±2.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.2</td>
<td>40±3.6</td>
<td>40±4.4</td>
<td>34±4.3</td>
<td>–</td>
<td>35±3.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II.1</td>
<td>54±4.5</td>
<td>52±2.8</td>
<td>60±3.5</td>
<td>–</td>
<td>45±3.4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A fifth CpG site is preceded by a 7 base pair T stretch (after bisulfite conversion), making it impossible to assess the exact percentage of cytosines compared to thymines for that particular site due to the limitations of the pyrosequencing technique. For each individual at least three separate analysis of different bisulfite conversions were performed. Average methylation percentages and confidence intervals are presented in this table. Methylation cut-off value was set at 10% according to the manufacturers guidelines.

doi:10.1371/journal.pgen.1004242.t002

Figure 7. Analysis of rs4851214 which maps to coding exon 14 of AFF3 using paired genomic DNA and cDNA templates from the unaffected carrier mother BLI.2 and the affected carrier son BLI.1 from family B. A: Both BLI.2 and BLI.1 are heterozygous for SNP rs4851214 in genomic DNA as T and C peaks are visible at this site. B: Analysis of cDNA from subject BLI.1, shows that only the C allele could be detected in this patient, indicating monoallelic expression, while in cDNA of subject BLI.2 the heterozygous T/C signal was observed, indicating transcription of both alleles.

doi:10.1371/journal.pgen.1004242.g007
that FRA2A carriers are haploinsufficient for AFF3, at least in a subset of tissues. A confident assignment of causality to the association of AFF3-associated repeat expansion mutations with neurodevelopmental anomalies is confounded by the rarity of the fragile site and the strong bias in clinical ascertainment. It is, however, intriguing that delay in motor and language development appears to be a common feature in the individuals presented here and this may represent a true delay in development rather than a fixed disability. AFF3 deficiency may then be involved in the speed of skill acquisition without impairing the developmental capacity.

A de novo microdeletion of 500 kb on chromosome 2q11.2 removing only AFF3 [50] has been reported in a girl with a severe multisystem disorder consisting of a mesomelic skeletal dysplasia (fibular agenesis, abnormal and triangular tibiae, short neck), urogenital tract malformations, delayed psychomotor development and recurrent apnoea leading to respiratory arrest at the age of 4 months. This clinical presentation is clearly very different to those associated with FRA2A but would be consistent with the expression pattern we demonstrate in mouse embryos. The clinical differences may be explained by the fact that the methylation of the repeat and thus the inactivation of the AFF3 gene presumably takes place several weeks after fertilization, so that development during the first weeks is not affected [51]. It is also plausible that the transcriptional silencing associated with FRA2A may by tissue specific given that the alternative promoter and apparent transcriptional silencing of AFF3 is associated with methylation of an AFF3 promoter and apparent transcriptional silencing of AFF3. It is currently difficult to unequivocally link FRA2A to a specific neurodevelopmental phenotype but it is plausible that haploinsufficiency for AFF3 in the developing brain is related to a true developmental delay and possibly mild intellectual disability.

### Materials and Methods

#### Ethics statement

The ethics committees of the participating study centers approved the study protocol and all participants gave their written informed consent. The study was in accordance with the principles of the current version of the Declaration of Helsinki. The fetal brain tissue was collected with informed written consent and ethical approval by Southampton and South West Hants LREC. The fetal tissue was obtained following surgical termination of pregnancy and staged according to the Carnegie Classification [54,55].

#### Family description: Clinical diagnosis and chromosome analysis

**Family A.** The proband (AII.4, Figure 1) was originally investigated at the age of 7.5-years for mild to moderate learning disability and enuresis. She was born at term following an uneventful pregnancy. There were no neonatal problems but her early motor and language development was reported to be slow. Her general health was good and her weight was on the 25th centile for her age. She attended a school for children with special educational needs. When last seen at the age of 20-years she was healthy and was working as a checkout operative in a high-street store and had no evidence of a significant functional neurocognitive deficit. Her elder sister (AII.3) had been investigated several years earlier for moderate global learning disability and had attended the same a school for children with special educational needs. Again she displayed no evidence of significant cognitive impairment when seen at the age of 26-years. Indeed she was very much valued in the workplace for remembering numerical codes for almost the entire stock inventory. AII.3 has a healthy daughter (AIII.1), born after an uneventful pregnancy. Evaluation of AIII.1

---

**Table 3. Clinical findings in FRA2A carriers.**

<table>
<thead>
<tr>
<th>Family</th>
<th>Individual</th>
<th>Sex</th>
<th>Age at last assessment (yrs)</th>
<th>Growth</th>
<th>Delayed motor development</th>
<th>Delayed speech and language development</th>
<th>Intellectual disability</th>
<th>Required special educational support</th>
<th>General health</th>
<th>Other features</th>
<th>FRA2A expression in peripheral blood lymphocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>II.3</td>
<td>Female</td>
<td>33</td>
<td>Normal</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>Good</td>
<td>Good</td>
<td>26%</td>
</tr>
<tr>
<td>A</td>
<td>II.4</td>
<td>Female</td>
<td>31</td>
<td>Normal</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>Good</td>
<td>40%</td>
<td>40%</td>
</tr>
<tr>
<td>A</td>
<td>III.1</td>
<td>Female</td>
<td>0.2</td>
<td>Normal</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>Good</td>
<td>Good</td>
<td>31%</td>
</tr>
<tr>
<td>A</td>
<td>II.1</td>
<td>Male</td>
<td>12</td>
<td>Normal</td>
<td>+</td>
<td>+</td>
<td>Moderate</td>
<td>+</td>
<td>Reasonable</td>
<td>Reasonable</td>
<td>40%</td>
</tr>
<tr>
<td>A</td>
<td>II.1</td>
<td>Female</td>
<td>13</td>
<td>Normal</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>−</td>
<td>Reasonable</td>
<td>Anal fissure</td>
<td>26%</td>
</tr>
</tbody>
</table>

In conclusion, we report a CGG repeat expansion mutation as the molecular cause of the fragile site FRA2A. FRA2A expression is associated with methylation of an AFF3 promoter and apparent transcriptional silencing of AFF3. It is currently difficult to unequivocally link FRA2A to a specific neurodevelopmental phenotype but it is plausible that haploinsufficiency for AFF3 in the developing brain is related to a true developmental delay and possibly mild intellectual disability.
at the age of 3 weeks revealed no phenotypic abnormality. No intellectual problems were apparent in any other relatives of the three-generation family tree. DNA analysis of the FRA2A locus was normal and permission to use the remaining peripheral blood DNA for research purposes was obtained from patient AII.4 (Figure 1). An Epstein-Barr-transformed lymphoblastoid cell line was established at ECACC (Cambridge, UK) from a peripheral blood sample of proband AII.4. The index patient showed FRA2A expression in 40% of the examined cells. At the age of 20-years, chromosome analysis was repeated and confirmed FRA2A expression, this time in 21% of the examined cells. Subjects AII.3 and AIII.1 expressed the fragile site FRA2A in respectively 26% and 31% of the examined cells. The unaffected father (subject AL1) showed FRA2A expression in 4% of his cells, whereas in two unaffected siblings and the mother no indications were found for FRA2A expression (Figure 1).

**Family B.** The proband (II.1, Figure 1) was born at 39 weeks after an uneventful pregnancy. He was the third child of a non-consanguineous Caucasian couple. There were no problems in the neonatal period. At 8 weeks of age, an anal fistula was diagnosed and required three surgical procedures between 5 and 8 months for cure. He developed mild asthma at 10 months of age. Food allergies were demonstrated at 12 months of age and were managed by dietary modification. His height and head circumference were within the normal range, but his development was slow. He had mild dysmorphic features, including telecanthus, slightly short palpebral fissures, smooth philtrum, thin upper lip and a small mouth. Psychological assessment at the age of 12 using the WISC-IV showed a full-scale IQ in the range 40–52 (<0.1 centile), within the moderate range of intellectual disability. The Vineland Adaptive Behaviour Scales 11 gave an Adaptive Behaviour Composite in the range 50–67 (0.7 centile), within the moderate range of intellectual disability. His parents and two elder brothers had normal intelligence and were not dysmorphic. Routine chromosomes, subtelomere FISH of chromosomes, molecular testing for fragile X syndrome and urinary amino acids/organic acids/subtelomere FISH of chromosomes, molecular testing for fragile X syndrome and urinary amino acids/organic acids/mucopolysaccharides gave normal results. The proband expressed the fragile site FRA2A in 40% of the examined cells. Fragile site expression was not examined in the other family members.

**Family C.** The proband (II.1, see Figure 1) was born at 33 weeks after an uneventful pregnancy. She had respiratory distress syndrome and was treated with surfactant and ventilated for five days. There were no significant complications in the neonatal period. Her early development was delayed and she suffered from intermittent asthma and required ventilator tubes for serious otitis media. At three years of age, she was seen because of speech delay – her expressive language was estimated to be at the 2 year level while receptive language and general development were assessed at the 2.5–3.0 year level. She was noted to be macrophagic, hypotonic and hyperreflexic. Height was normal. At 13 years she is in an appropriate class in high school and undertakes all subjects, except mathematics, with her peers, but struggles to keep up. She has poor concentration, is easily distractible and does not like changes in routine or to immediate expectations. She is doing well socially. The following investigations gave normal results: CT brain scan, urine amino acids and organic acids, chromosomes, creatine kinase and thyroid function tests. The proband showed FRA2A expression in 26% of the examined cells. Fragile site expression was not examined in the other family members.

**Fluorescent in situ hybridisation (FISH) mapping**

Peripheral blood lymphocyte-derived metaphase chromosome preparations from individual AII.3 were obtained using standard methods. An AFF3-containing BAC-clone from the RPC11 library, RP11-549H5 (AC092667), and clones mapping centromeric (RP11-436F6, AC010730) and telomeric (RP11-506F3, AC074307) to AFF3 were obtained from the BACPAC Resource Center (Oakland, California, USA). Long Range-PCR (LR-PCR) was used to generate probes of 10 kb and 18 kb situated respectively immediately 5’ and 3’ to the promoter region of AFF3. The following primer pairs were used: L10K (forward 5’-TGCAGGAATGAAATGAGGGGGAAG-3’ and reverse 5’-TGGCCTCTGGGTGTGGACACATCAAC-3’) and L10K (forward 5’-ACAGGTGGGTTAGGTACGGAG-3’ and reverse 5’-TGTCATATGGTTTCATGGACCT-3’). LR-PCR was performed using the Expand Long Template PCR System (Roche, Basel, Switzerland) according to the manufacturer’s instructions. The amount of BAC DNA used per reaction was 5–10 ng. All probes were labelled with digoxigenin-11-dUTP or biotin-16-dUTP (Roche, Indianapolis, IN) by nick translation. DNA hybridisation and antibody detection were carried out as described previously [56]. At least five metaphases were analysed for each hybridisation, using a Zeiss Axiosplan 2 fluorescence microscope equipped with a triple band-pass filter (#83000 for DAPI, FITC and Texas Red; Chroma Technology, Brattleboro, VT). Images were collected using a cooled CCD camera (Princeton Instruments Pentaxam, Roper Scientific, Trenton, NJ) and analysed using IPLab software (Scanalytics, Vienna, VA).

**PCR amplification and hybridization of the FRA2A-associated CGG repeat**

PCR amplification of the normal FRA2A CGG repeat was performed with the aid of 2.5× PCR Enhancer solution (Invitrogen, Carlsbad, CA, USA) using a forward primer P1 (5’-GGCGGTTTGGGAGGAGAGG-3’) and a reverse primer P2 (5’-CTTGGCAGGCAGGGACACTCAAGAG-3’) derived from the sequences flanking the repeat. PCR products were sequenced and subsequently analysed by use of an ABI Prism 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

A Southern blot was created by digesting 10 μg of DNA, extracted from blood or Epstein-Barr-virus transformed cells, with the restriction enzymes HindIII and NotI (Fermentas GmbH, St. Leon-Rot, Germany) in separate reactions. The digested DNA was then separated by electrophoresis on a 0.7% agarose gel. No ethidium bromide was added during this electrophoresis step to avoid product-related smearing on the gel that would cause overestimation of the mosaicism of repeat sizes [57]. After subsequent denaturation and neutralisation the DNA fragments were transferred to Hybond N membranes. Hybridisation was performed at 65°C using a specific 32P-labeled 992 bp PCR probe (forward primer 5’-AGCCTTTGTCTCTGGGAAATGCTGTCTCTAAAT-3’ and reverse primer 5’-GGAAAGCACCAGATTAGTGATCCAGCTAGAAAAGGGTG-3’). Repeat primed PCR was performed to interrogate the number of CGG repeats in the AFF3 gene with Asuragens CGG Repeat Primed PCR system designed for detection of Fragile X expanded alleles. Triplet repeat primed PCR (TP-PCR) uses a locus-specific forward primer that flanks the repeat. The reverse PCR primer of the primer pair is designed to hybridise within the CGG repeat region as it contains a (GCC)_5 tail. This generates amplicons of various sizes as the reverse primers bind to multiple locations during TP-PCR. As the number of CGG repeats increases, a characteristic ladder profile appears on the fluorescence electropherogram enabling the rapid and inexpensive identification of expanded repeats that may have been missed using current PCR methods. Samples were PCR-amplified by preparing a master mixing containing 11.45 μl of GC-rich AMP buffer, 0.25 μl of
analysed using the ABI Prism 3130 Genetic Analyzer. Rox 1000 standard. After a brief denaturation step, samples were of the PCR product was added to a mix with 11 primer (5'-CACGAGAGAGGG-3'), 0.5 μl of CGG primer (5'-TACGGATCCTGGTAGGATCCGGCGGCGCCGC-3'), 0.5 μl of nuclease-free water, and 0.05 μl of GC-rich polymerase mix from Asuragen (Austin, TX). 2 μl of the DNA sample, typically at 20 ng/μl, was added before transferring the plate to a thermal cycler (9700, Applied Biosystems, Foster City, CA). Samples were amplified with an initial heat denaturation step of 95°C for 5 minutes, followed by 10 cycles of 97°C for 35 seconds, 62°C for 35 seconds, and 68°C for 4 minutes, and then 20 cycles of 97°C for 35 seconds, 62°C for 35 seconds, and 68°C for 4 minutes with a 20 second autoextension at each cycle. The final extension step was 72°C for 10 minutes. After PCR, 2 μl of the PCR product was added to a mix with 11 μl HDF and 2 μl Rox 1000 standard. After a brief denaturation step, samples were analysed using the ABI Prism 3130 Genetic Analyzer.

Methylation analysis of the AFF3 promoter

The methylation status of the AFF3 associated CGG repeat and the surrounding region, was analysed by bisulphite sequencing. Genomic DNA collected from lymphoblastoid cell lines and saliva (subject AII.1) was bisulphite-treated using the EpiTect Bisulfite Kit (Qiagen, Venlo, Netherlands) according to manufacturer's guidelines. Bisulphite treatment converts all non-methylated cytosines into thymines, while methylated cytosines remain unchanged. Primers specific for the methylated bisulphite converted DNA (forward 5'-GGTGAGAATAAAAAAGAGGAC-3' and reverse 5'-CCTCAACCAACCTAATAACC-3') were designed. After PCR amplification, the CGG surrounding area (chr2:100721494–990721911; hg19) was sequenced using an ABI Prism 3130 DNA sequencer. Moreover we have performed pyrosequencing analysis by bisulfite sequencing. The methylation status of the associated CGG repeat and promoter Aff3 was analysed by bisulfite sequencing. The WISH protocol and OPT scanning was performed exactly as previously described [58].

Gene-expression analysis

The expression pattern of AFF3 in human tissues was studied using a multiple-tissue Northern blot (FirstChoice Northern Human Blot I, Ambion, Austin, TX, USA). The specific AFF3 probe was a 653-bp PCR product [forward primer 5'-TATCGAGTGGAAAATGCAA-3' and reverse primer 5'-TTAGGTTCCCTATGAGGTTG-3'] and radiolabelled by the addition of 32P-dATP and 32P-dCTP (MP, Irvine, California, USA). Hybridisation was performed according to the manufacturer’s instructions.

Total RNA-sequencing data from the Illumina Human Body Map 2.0 project (ESE03611) was obtained from the NCBI Gene Expression Omnibus. Data from brain (ERR030882, female, 77y), ovary (ERR030874, female, 47y) and lymph node (ERR030878, female, 86y) was downloaded in the form of 2×50 bp reads and imported into CLC genomics workbench v6.01. Transcriptomics analysis was performed within CLC Genomics using the human reference genome version hg19. Default settings were used, apart from a smaller expected insert size of 50 bp. Additionally total RNA was isolated from the human fetal brain tissues (FB1 54 gestational days (GD), FB2 47 GD, FB3 59 GD) according to the Trizol (Invitrogen) protocol. The preparation of ampiclon libraries and RNA-Seq analysis were performed following standard Illumina TruSeq protocols and reads of length 50 bp were produced on the Illumina GAIIx platform. The fetal tissue was obtained following surgical termination of pregnancy and staged according to the Carnegie Classification [54,55]. CAGE tag data was obtained from the FANTOM4 consortium as both pre-defined CAGE tag clusters (http://fantom.gsc.riken.jp/download/Tables/human/CAGE/promoters/tag_clusters/ and http://fantom.gsc.riken.jp/4/download/Tables/human/CAGE/mapping/). Coordinates were converted from the hg18 reference genome assembly to hg19 using LiftOver (http://genome.ucsc.edu/cgi-bin/hs/liftOver). Statistical analysis was performed R (http://www.R-project.org/; version 3.0.0).

The AFF3 transcript NM_002285 (http://www.ncbi.nlm.nih.gov/) was searched for cSNP’s. The cSNP’s in FAA2A patients were tested by PCR followed by sequencing at the genomic and at the cDNA level. RNA was isolated from Epstein-Barr-transformed lymphoblastoid cells using Trizol (Invitrogen, Carlsbad, CA, USA) and converted to cDNA using Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The following primer sets were used: SNP1 (rs4851214) in exon 14 (forward primer 5'-AGGTGAGAAGAGGA-GAATTGAACA-3' and reverse primer 5'-ATAGGAGGCTTTGAGGATTA-3') and SNP2 (rs13427251) in exon 25 (forward primer 5'-GGTTGTCTGGTATGGTATTA-CAC-3' and reverse primer 5'-GGATCGACCATCTGTC- TAA-3'). Sequencing products were analysed on an ABI Prism 3130 automatic sequencer.

The AFF3 riboprobe for whole mount in situ hybridisation to mouse embryos was generated by in vitro transcription from a PCR template amplified from the AFF3 3'UTR using mouse genomic DNA as a template. T3 (for sense probe) and T7 (for antisense probe) binding sites were added to the forward (5'-AATTAACCTTCACTAAGGGCTTCTCCACCCGGGAATCCAGAAT-3') and reverse (5'-TATAGAATCTACTCTATTAGGACCCATGGCACCACCTCTCT-3') primers. The WISH protocol and OPT scanning was performed exactly as previously described [58].

Mutation analysis of the AFF3 gene and marker analysis

All coding exons of the AFF3 gene were PCR amplified at the genomic level using standard protocols for all patients and relatives to exclude the presence of any other disease-causing mutation. PCR products were enzymatically purified and sequenced. Sequences were analysed with an ABI Prism 3130 DNA sequencer.

For the marker analysis, genomic DNA was isolated from peripheral blood from all available family members using standard procedures. Highly polymorphic microsatellite markers, D2S2209 and D2S2311, were selected from the Marshfield genetic map in the proximity of the repeat. These markers are both dinucleotides with an average heterozygosity of 71%. Analysis was performed by a Go Taq DNA polymerase mediated PCR, with fluorescently labeled primers. Fragment analysis of amplified products was performed using an ABI PRISM 3130 XL Genetic Analyzer (Applied Biosystems). Allele identification was done with Gene mapper v3.7 software (Applied Biosystems).

Supporting Information

Figure S1 CGG-repeat region in AFF3 intron 2. Sequence of the CGG-repeat region in intron 2 of the AFF3 gene shown in telomer-centric centromeric orientation. The CGG repeat is shown in bold blue text. The repeat lies within the 134 bp region that is deleted in subject AII.4 which is shown in bold black text. Forward and reverse primers used for the amplification of the CGG repeat are indicated with blue arrows. The primers used for bisulphite sequencing (chr2:100721494–100721911; hg19) are indicated with
orange arrows and CpG sites that were analysed with bisulfit pyrosequencing are represented in bold orange text.

**Figure S2** A: Fragment-length analysis of regular PCR and TP-PCR generated products of the CGG repeat in the AFF3 gene of family A. Fluorescently-labeled PCR products of all individuals of family A were separated by capillary electrophoresis on an ABI PRISM 3130 XL Genetic Analyzer. For every individual a PCR covering the entire repeat was analyzed in addition to a repeat primed PCR (Asuragen). Individual AL1 appeared homozygous for a repeat with 8 units as no fading repeat-signal is present after repeat-primed PCR (right corner). For individual AII.4 the 134 bp-deletion of the repeat and surrounding region is clearly detected in addition to a short 8-unit repeat. An expanded allele of over 300 units is present in this individual as shown with repeat primed PCR. This expanded allele could not be covered by regular PCR covering the entire repeat. In individuals AII.3 and AIII.1 a normal range repeat of 8 and 18 repeated units respectively was detected in addition to an expanded allele containing over 300 units. B: Fragment-length analysis of regular PCR and TP-PCR generated products of the CGG repeat in the AFF3 gene of family B. In individual BI.2 one normal range allele with 15 repeated units was identified. In addition, a second slightly expanded allele of about 120 repeated units was detected by regular PCR covering the repeat. This expansion was confirmed with repeat primed PCR. In individual BI.1 a normal range repeat of 8 was detected in addition to an expanded allele containing over 300 units. The trace labelled FR_blanco represents a blanc reference lane. C: Fragment-length analysis of regular PCR and TP-PCR generated products of the CGG repeat in the AFF3 gene of family C. The father of family C, CI.1, is heterozygous for the number of repeated units, displaying two alleles with respectively 5 and 8 repeated units. In the mother, CI.2, a second slightly expanded allele with 106 repeated units was detected in addition to a normal range allele with 17 CGG-units by regular PCR. This expansion was confirmed with repeat primed PCR. In individual CII.1 a normal range repeat of 8 was detected in addition to an expanded allele containing over 300 units. For each individual of this family the raw analysis data of the genetic analyzer are displayed in the upper right corner. The trace labelled FR_blanco represents a blanc reference lane.

**Figure S3** Genotyping results of the microsatellite marker analysis on family A with markers D2S2209 and D2S2311. From the combination of both markers we can conclude that both sisters (AII.3 and AII.4) have inherited a different allele from their father (AI.1), while they share a common allele that is probably inherited from the mother. It is again this allele that was passed on to the granddaughter (AIII.1). As individuals AII.3, AII.4 and AIII.1 all carry an expanded and hypermethylated allele for the AFF3 associated repeat, it can be presumed that the expansion was probably inherited from the mother.

**Figure S4** a: Bisulfite sequences of family A. After bisulfit treatment of the genomic DNA from lymphoblastoid cell lines and saliva (subject AII.1) of all available family members, DNA sequences of the region located at chr2:100721494–100721911; hg19 were analysed with an ABI Prism 3130 DNA sequencer. This region covers 50 separate CpG dinucleotides of which nine are shown in this figure. Methylation patterns were consistent across all 50 CpG sites for each individual. Blue (C-) peaks at CpG-sites in addition to a red T-signal indicate the presence of at least partial methylation. b: Bisulfite sequences of family B. c: Bisulfite sequences of family C. (TIF)

**Acknowledgments**

We want to thank the families and patients for their collaboration, Kim Debacker and Birgitta Winnepennixx for their help with the experiments, Professor Wim van den Berge for access to his pyrosequencer and Marie Shaw, Olivia Beck, Gaby Munteau and Lieve Wiericx for help with cell lines.

**Author Contributions**

Conceived and designed the experiments: SM LR DIW JG DRF RFK. Performed the experiments: SM LR HB ER HM ED JR. Analyzed the data: SM LR MST CSRC GV JG HM DRF RFK. Contributed reagents/materials/analysis tools: DIW JG DRF RFK. Wrote the paper: SM LR MST_JG DRF RFK. Clinical geneticists consultation: EH. Collecting patients: GT JG DRF.

**References**

33. Ma C, Staudt L (1996) LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias. Blood 87: 734–745.


41. Taki T, Kano H, Tanabashi M, Sako M, Yamagawa M, et al. (1999) AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(3;11) (q31.1;q32). Proc Natl Acad Sci USA 96: 14535–14540.


